Compare Gogoro Inc (GGR) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Nuwellis Inc — how do they compare? Gogoro Inc trades at $3.15 (market cap $56.21M), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Gogoro Inc is far larger — about 25.6× Nuwellis Inc's market cap, and Gogoro Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Nuwellis Inc for 26 Days on average.
| GGR | NUWE | |
|---|---|---|
Market Cap | $56.21M | $2.20M |
Volume | 14,026 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $146.65 |
52-Week Low | $2.20 | $0.68 |
Typical Hold Time | 14 Days | 26 Days |
Enterprise Value | $342.65M | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gogoro (GGR) trades at $3.15, up 5.35% today, but faces bearish technical signals and weak profitability, with a net loss of $79.97M in 2025. Revenue grew modestly to $281.48M, yet margins remain negative. Recent news highlights board changes and a $61.8M equity investment, signaling internal restructuring efforts. The stock shows oversold conditions with an RSI of 27.68, but moving averages indicate a downtrend.
The outlook is cautious due to persistent losses and high debt-to-asset ratio of 60%, though low valuation ratios (P/S 0.16, P/B 0.5) may attract value investors. Risks include execution challenges and competitive pressures. Analysts are neutral with 100% hold ratings, reflecting uncertainty about near-term turnaround.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
